3 terminated. 3 Phase 1, 3 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 3 | Terminated 3 |
| Phase 2 | 3 | Terminated 3 |
Follow batiraxcept: new trials by email Literature Review of batiraxcept trials Research Report on batiraxcept
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Safety and Efficacy Study of AVB-S6-500 (Batiraxcept) in Patients With Advanced Pancreatic Adenocarcinoma batiraxcept, Nab paclitaxel, Gemcitabine - Pancreatic Adenocarcinoma | Phase 1 / Phase 2 | Terminated | Aravive, Inc. | 34 | 2021-07-28 | 2023-10-30 |
| Safety and Efficacy Study of AVB-S6-500 (Batiraxcept) in Patients With Advanced or Metastatic Clear Cell Renal Cell Carcinoma Batiraxcept, Cabozantinib (Cabo), Nivolumab - Clear Cell Renal Cell Carcinoma | Phase 1 / Phase 2 | Terminated | Aravive, Inc. | 72 | 2021-02-26 | 2023-10-30 |
| AVB-S6-500 and Durvalumab in Treating Patients With Platinum-Resistant or Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer Batiraxcept, Durvalumab - Platinum-Resistant Fallopian Tube Carcinoma, Platinum-Resistant Ovarian Carcinoma | Phase 1 / Phase 2 | Terminated | M.D. Anderson Cancer Center | 12 | 2019-12-03 | 2025-06-11 |
Adenocarcinoma (1) · Carcinoma, Renal Cell (1) · Fallopian Tube Neoplasms (1) · Kidney Diseases (1) · Kidney Neoplasms (1) · Neoplasm Metastasis (1) · Ovarian Neoplasms (1) · Recurrence (1) · Urologic Neoplasms (1)
Aravive, Inc. (2) · M.D. Anderson Cancer Center (1)
United States (3)
Amir A Jazaeri (1)